On July 18, 2022, Cells for Cells ("C4C"), a clinical-stage biotech company pioneering allogeneic stem cell and stem-cells-derived therapeutics for high-impact chronic diseases, announced a 6-month follow-up of the ground-breaking clinical data from the first-ever patient dosed with an exosome-produced therapy for osteoarthritis. The results were made public at an extracellular vesicles (EVs) signature series during the ISCT (International Society for Cell & Gene Therapy) annual meeting in San Francisco and the ISEV (International Society for Extracellular Vesicles) meeting in Lyon, France. Dr. Maroun Khoury, Chief Scientific Officer of C4C, presented the results of the first trial evaluating the safety and efficacy of exosome biotherapeutics in joint disease. This study reported an unprecedented WOMAC score reduction six months after a single administration of XO-101, C4C's flagship exosome therapy derived from mesenchymal stem cells (MSCs).